/SNPX
SNPX Stock - Synaptogenix, Inc.
Healthcare|BiotechnologyNASDAQ
$7.85+29.86%
+$1.80 (+29.86%) • Jun 30
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.97
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.68
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $8.63
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SNPX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.77 – $7.93
TARGET (TP)$9.03
STOP LOSS$7.22
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.30
52W High$8.94
52W Low$1.84
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-5,580 | $-6,347 | $-5,714 | $-4,966 | $-4,872 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-6,810,732 | $-8,313,854 | $-26,360,996 | $-12,618,307 | $-9,456,410 |
| Net Income | $-12,768,549 | $-6,038,504 | $-5,458,067 | $-12,604,087 | $-14,249,984 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-10.99 | $-29.56 | $-20.35 | $-62.87 | $-300.78 |
Company Overview
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SNPXBeat Rate
45%
Last 11 quarters
Avg Surprise
-245.7%
EPS vs Estimate
Beats / Misses
5/6
Last 12 quarters
Latest EPS
$-1.56
Q4 2025
EPS Surprise History
Q2 24
+106.6%
$0.63vs$-9.50
Q2 24
No data
Q3 24
+35.5%
$-1.18vs$-1.83
Q4 24
-134.9%
$-4.58vs$-1.95
Q1 25
-111.7%
$-4.36vs$-2.06
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | — | $-1.56 | — | — |
Q3 2025 | Aug 13, 2025 | — | $-1.18 | — | — |
Q2 2025 | May 15, 2025 | — | $0.04 | — | — |
Q1 2025 | Mar 27, 2025 | $-2.06 | $-4.36 | -111.7% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-1.95 | $-4.58 | -134.9% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-1.83 | $-1.18 | +35.5% | ✓ BEAT |
Q2 2024 | May 15, 2024 | — | $-0.41 | — | — |
Q2 2024 | Apr 1, 2024 | $-9.50 | $0.63 | +106.6% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-9.25 | $-0.75 | +91.9% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-8.50 | $-34.75 | -308.8% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.56 | $-6.50 | -1060.7% | ✗ MISS |
Q1 2023 | Mar 21, 2023 | $-0.46 | $15.75 | +3523.9% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.48 | $-10.75 | -2139.6% | ✗ MISS |
Q3 2022 | Aug 5, 2022 | $-0.48 | $-13.50 | -2712.5% | ✗ MISS |
Q2 2022 | May 13, 2022 | $-0.51 | $-0.47 | +7.8% | ✓ BEAT |
Q1 2022 | Mar 29, 2022 | — | $-15.57 | — | — |
Q4 2021 | Nov 12, 2021 | — | $-11.81 | — | — |
Q3 2021 | Aug 13, 2021 | — | $-14.44 | — | — |
Q2 2021 | May 14, 2021 | — | $-26.56 | — | — |
Q1 2021 | Mar 30, 2021 | — | $-40.61 | — | — |
Latest News
Loading news...
Frequently Asked Questions about SNPX
What is SNPX's current stock price?
Synaptogenix, Inc. (SNPX) is currently trading at $7.85 per share. The stock has moved +29.86% today.
What is the analyst price target for SNPX?
No analyst price targets are currently available for this stock.
What sector is Synaptogenix, Inc. in?
Synaptogenix, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SNPX's market cap?
Synaptogenix, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does SNPX pay dividends?
No, Synaptogenix, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMTI
Applied Molecular Transport Inc.
$0.26
Mkt Cap: $0.0B
APGN
Apexigen, Inc.
$0.39
Mkt Cap: $0.0B
CYCC
Cyclacel Pharmaceuticals, Inc.
$6.37
Mkt Cap: $0.0B
GLS
Gelesis Holdings, Inc.
$0.16
Mkt Cap: $0.0B
HURA
TuHURA Biosciences, Inc.
$0.82
Mkt Cap: $0.0B
KRRO
Korro Bio, Inc.
$7.88
Mkt Cap: $0.1B
NTBL
Notable Labs, Ltd.
$0.25
Mkt Cap: $0.0B
OBSV
ObsEva S.A.
$0.10
Mkt Cap: $0.0B
SCPX
Scorpius Holdings, Inc.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to SNPX for comparison